Scholarlink

Purpose <p>To outline supportive-care considerations for using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during chemotherapy and/or radiotherapy, focusing on nutrition, body composition, and treatment tolerance.</p> Methods <p>This Comment addresses the supportive-care implications of this situation and draws on evidence from obesity trials, cardiovascular outcomes trials, pharmacokinetic studies, and oncology literature on sarcopenia and treatment tolerance.</p> Results <p>GLP-1 RAs improve cardiometabolic risk and, in selected high-risk populations, reduce major adverse cardiovascular events. However, body-composition studies indicate that their weight loss is not exclusively adipose; approximately 20–30% may be lean mass. In oncology, low skeletal muscle mass has been associated with higher rates of severe toxicity, more dose modifications, and worse survival. Delayed gastric emptying may lower maximum concentration and delay time to maximum concentration of oral co-medications while usually preserving overall exposure in non-oncology settings.</p> Conclusion <p>Although GLP-1 RAs have preventive and cardiometabolic benefits, these do not exclude possible concerns during active cancer therapy. Systematic screening, dietetic support, resistance exercise, and body-composition monitoring should guide initiation or continuation decisions during active treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GLP-1 receptor agonists during chemotherapy and radiotherapy: a supportive care call for nutrition-centred monitoring in the era of widespread prescribing

  • 期刊论文

  • 发表日期：

    2026年4月20日

查看全文
  • Aurélia Alati,
  • Nathaniel Scher,
  • Alain Toledano

摘要

Purpose

To outline supportive-care considerations for using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during chemotherapy and/or radiotherapy, focusing on nutrition, body composition, and treatment tolerance.

Methods

This Comment addresses the supportive-care implications of this situation and draws on evidence from obesity trials, cardiovascular outcomes trials, pharmacokinetic studies, and oncology literature on sarcopenia and treatment tolerance.

Results

GLP-1 RAs improve cardiometabolic risk and, in selected high-risk populations, reduce major adverse cardiovascular events. However, body-composition studies indicate that their weight loss is not exclusively adipose; approximately 20–30% may be lean mass. In oncology, low skeletal muscle mass has been associated with higher rates of severe toxicity, more dose modifications, and worse survival. Delayed gastric emptying may lower maximum concentration and delay time to maximum concentration of oral co-medications while usually preserving overall exposure in non-oncology settings.

Conclusion

Although GLP-1 RAs have preventive and cardiometabolic benefits, these do not exclude possible concerns during active cancer therapy. Systematic screening, dietetic support, resistance exercise, and body-composition monitoring should guide initiation or continuation decisions during active treatment.